Walk Ahead for a Brain Tumor Cure on Oct. 21
Thousands expected at annual event
Event Information (passed)
The ninth annual Walk Ahead for a Brain Tumor Cure is Sunday, Oct. 21, 2018 at Sawyer Point.
- Registration begins at 7:30 a.m.
- Timed 5K run begins at 8:30 a.m.
- 5K walk begins at 9 a.m.
- Wheelchair friendly 2K begins at 9 a.m.
Thousands of walkers and runners will support research and educational efforts of the University of Cincinnati Brain Tumor Center at the University of Cincinnati Gardner Neuroscience Institute.
Now nearly a decade in existence, Walk Ahead 2018 will have raised $2 million over its entire lifetime, following the 2018 event.
Brain tumors are not uncommon. More than 200,000 people are stricken with brain tumors in America every year. During the last two decades, the frequency of brain tumors has increased 22 percent overall and 55 percent in people over 65 years of age. The University of Cincinnati Brain Tumor Center is a regional destination for brain tumor patients, providing compassionate care while striving to find causes and cures. The funds raised through Walk Ahead advance the innovative research necessary to developing new treatments.
Related Stories
UC experts say proper produce washing is key defense against Cyclospora
July 17, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
UC students organize free health clinic in community
July 15, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
University of Cincinnati advances FLASH radiation therapy with new clinical trial
July 15, 2026
UC Cancer Center researchers led the FAST-02 trial, showing ultra-high-dose-rate FLASH proton therapy near the heart and lungs safely reduced pain from thoracic bone metastases.